Navigation Links
Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN)
Date:8/24/2009

ALISO VIEJO, Calif., Aug. 24 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced preliminary results from its Phase IIa proof-of-concept clinical trial of retigabine for the treatment of pain associated with postherpetic neuralgia (PHN), a painful and common complication of shingles. While retigabine was generally well tolerated, the study did not meet its pre-specified primary efficacy endpoint. Further detailed analyses are warranted and are ongoing.

"As is typical in many proof-of-concept studies, these results are inconclusive at this time with regard to the potential utility of retigabine in PHN patients," stated J. Michael Pearson, chairman and chief executive officer. "The treatment duration was relatively short and with limited statistical powering for the study overall. There are many additional analyses that have yet to be undertaken and these will be performed over the next several months. Moreover, given that the provisional results from this study will not impact the submission of our New Drug Application for retigabine in epilepsy, we remain focused on the submission as our number one priority."

The study was a randomized, double-blind, placebo-controlled Phase IIa proof-of-concept study with 187 patients randomized 2:1 of retigabine versus placebo for a treatment period of up to 10 weeks. The study was conducted in approximately 50 trial locations. Study patients were titrated to their individually determined maximum tolerated dose within the range of 300 mg to 900 mg per day. The primary outcome assessment was the comparison of the average pain intensity over the last seven days of maintenance therapy with retigabine versus placebo. Pain intensity was measured on a standard 0 - 10 numerical rating scale.

About PHN

PHN is a painful complication of Herpes Zoster, a condition commonly known as "shingles." Shingles results from a reactivation of the Varicella Zoster virus, the same agent that causes chicken pox. Patients with shingles typically have a painful blistering rash that lasts for several weeks. PHN occurs when nerve fibers are damaged during an outbreak of shingles, causing chronic and often excruciating pain that may continue for months or years. Currently available treatments for PHN include topical medications, over-the-counter analgesics, tricyclic antidepressants and antiepileptics.

About Retigabine

Retigabine, a first-in-class neuronal potassium channel opener, is currently in late-stage development as an adjunctive treatment for patients with partial-onset seizures. In Phase III epilepsy trials, retigabine was shown to be efficacious with a demonstrated reduction in monthly seizure rates.

Retigabine Important Note

Retigabine has not been found by the Food and Drug Administration (FDA) or any other regulatory agency to be safe or effective in the diagnosis, mitigation, treatment or cure of any disease or illness. It may not be sold or promoted in the United States unless and until the FDA has approved a NDA. Similar restrictions apply in other countries.

The most common side effects associated with retigabine to date include somnolence, dizziness, confusion, speech disorder, vertigo, tremor, amnesia, abnormal thinking, abnormal gait, paresthesia, diplopia, incoordination, nervousness, abnormal vision, asthenia, headache, nausea and diarrhea.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding retigabine's potential in the treatment of postherpetic neuralgia and the impact of this clinical study on the filing of the New Drug Application. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

(Logo:http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)

    Contact:
    Laurie W. Little
    Valeant Pharmaceuticals
    949-461-6002
    laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Valeant Pharmaceuticals Reports Second Quarter Financial Results
2. Valeant to Acquire Tecnofarma, A Mexican Generic Company
3. Valeant Pharmaceuticals to Announce 2009 Second Quarter Results on August 4, 2009
4. Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal
5. Valeant Announces Increase to Securities Repurchase Program
6. Valeant to Acquire Polish Dermatology Company
7. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
8. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
9. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
10. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
11. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... ... ... Breast Surgeon, Dr. Dennis Holmes of 90210 Surgery Medical Center will review ... fits in the treatment paradigm at Susan G. Komen San Diego’s Annual Dinner Symposium, ... cancer and wellness experts to share the latest innovations in breast cancer research, treatment ...
(Date:3/1/2017)... ... March 01, 2017 , ... Award-winning medical group Allied Anesthesia ... mission trips in underdeveloped nations, averaging more than one trip per year since 1998. ... on the website features the details of his charitable work. Char has been ...
(Date:3/1/2017)... ... March 01, 2017 , ... Granite Peaks ... cancer screening rates by supporting the 80% by 2018 initiative, led by the ... the National Colorectal Cancer Roundtable (an organization co-founded by ACS and CDC). , ...
(Date:3/1/2017)... ... March 01, 2017 , ... March 2017 – All year round ... don’t want to stop training to brave the cold weather, snow or ice. Treadmill ... small incline can help protect these vulnerable joints, says orthopaedic surgeon Kevin D. Plancher, ...
(Date:3/1/2017)... ... March 01, 2017 , ... “There is Comfort for the Soul”: a ... author in their all-too-brief time together, and the soul-healing comfort provided by God’s presence ... creation of published author, Jerie A. Tau, a dog-loving medical professional whose work takes ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... Research and Markets has announced the addition of the ... report to their offering. ... This analysis is one of the most accurate studies ... date financial data derived from varied research sources to present unique ... the market during the next five years, including a deep dive ...
(Date:3/1/2017)... 2017  Aethlon Medical, Inc. (Nasdaq: AEMD), announced ... European Patent Number 2591359, entitled "METHODS AND COMPOSITIONS ... exosomes have emerged as a significant diagnostic and ... conditions, including cancer, infectious viruses, tuberculosis, Alzheimer,s, and ... is an important addition to Aethlon Medical,s patent ...
(Date:3/1/2017)... DUBLIN , Mar 01, 2017 Research and ... of In-Vitro Diagnostics Tests for Cancer & Infectious Diseases" report to ... Did you ... Sales & Marketing, U.S. Breast/Colon at Genomic Health, Inc.. - Beijing ... manufacturing base for the production of infectious diseases diagnostics in ...
Breaking Medicine Technology: